Thus, the use of siltuximab could also be considered in patients receiving tandem CD19/CD22 CAR T-cell therapy, in which clinical evidence is showing promise as an alternative to patients with r/r B-ALL who relapse to current CD19 CAR T-cell approaches [34, 35]. Here, CD22 is linked to acute lymphoblastic leukemia.